<DOC>
	<DOCNO>NCT00324597</DOCNO>
	<brief_summary>RATIONALE : AMG 706 may stop growth cancer cell block blood flow cancer block enzyme need cell growth . Drugs use chemotherapy , gemcitabine , work different way stop growth cancer cell , either kill cell stop divide . Giving AMG 706 together gemcitabine may kill cancer cell . PURPOSE : This phase I trial study side effect best dose AMG 706 give together gemcitabine treat patient advance solid tumor lymphoma .</brief_summary>
	<brief_title>AMG 706 Gemcitabine Treating Patients With Advanced Solid Tumors Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose safety AMG 706 give combination gemcitabine hydrochloride patient advance solid tumor lymphoma . Secondary - Determine pharmacokinetic profile regimen patient . OUTLINE : This multicenter , open-label , dose-escalation study AMG 706 . Patients receive oral AMG 706 daily day 2-56 gemcitabine hydrochloride IV 30 minute day 1 , 8 , 15 , 22 , 29 , 36 , 43 course 1 . For subsequent course , patient receive oral AMG 706 day 1-28 gemcitabine hydrochloride IV 30 minute day 1 , 8 , 15 . Treatment repeat every 4 week 10 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos AMG 706 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 3 6 patient experience dose-limiting toxicity . During first course study treatment , patient undergo blood collection periodically pharmacokinetic analysis . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : Approximately 18 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced solid tumor lymphoma Must measurable disease outside previously irradiated field OR regrowth tumor within previously irradiate field Must candidate gemcitabine hydrochloride treatment , opinion investigator No untreated symptomatic brain metastases No tumor direct bowel invasion No hematological malignancy No nonsmall cell lung cancer squamous cell histology large central tumor ( lesion ≥ 3 cm locate adjacent within hilum mediastinum ) PATIENT CHARACTERISTICS : ECOG performance status 02 Not pregnant No nursing 6 month completion study treatment Fertile patient must use effective contraception 6 month completion study treatment Negative pregnancy test Able swallow oral medication Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 40 mL/min Albuminadjusted calcium ≥ 8 mg/dL Urine protein &lt; 30 mg/dL urinalysis &lt; 1+ dipstick OR &lt; 500 mg 24hour urine collection AST ALT ≤ 2.5 time upper limit normal ( ULN ) ( 5.0 time ULN presence liver metastasis primary hepatic neoplasm ) Bilirubin ≤ 2 time ULN PT ≤ 2.0 INR PTT ≤ 1.5 time ULN Systolic blood pressure ( BP ) ≤ 145 mm Hg diastolic BP ≤ 85 mm Hg ( stable antihypertensive medication allow ) No myocardial infraction within past year No arterial thrombosis deep vein thrombosis within past year No unstable angina No congestive heart failure No New York Heart Association class IIIIV cardiac disease No unstable uncontrolled disease condition relate impact cardiac function No HIV positivity No condition would preclude study participation , compliance , followup assessment PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior enrollment study At least 1 month since prior investigational device drug trial At least 1 month since prior major surgical procedure At least 3 week since prior systemic chemotherapy At least 2 week since prior radiotherapy At least 2 week since prior rifampin phenobarbital At least 1 week since prior treatment follow : Ketoconazole Itraconazole Clarithromycin Erythromycin Cyclosporine tacrolimus Nefazodone Herbal medication contain Hypericum perforatum ( St. John 's wort ) At least 1 week since prior concurrent warfarin Concurrent prophylactic anticoagulation therapy ( e.g. , lowdose warfarin [ ≤ 2 mg/day ] low molecular weight heparin ) venous arterial access device allow No prior concurrent kinase insert domainreceptor inhibitor No concurrent chemotherapy , radiotherapy , hormonedirected cancer therapy , tumordirected antibody therapy Gonadotropin releasinghormone agonist therapy allow No concurrent interferon No concurrent grapefruit juice whole grapefruit No concurrent standard investigational drug antitumor treatment , include ckit , plateletderived growth factor , vascular endothelial growth factor , epidermal growth factor inhibitors No elective surgery 2 week completion last dose AMG 706</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>Waldenström macroglobulinemia</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>post-transplant lymphoproliferative disorder</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
</DOC>